Innate Pharma (IPHA) Research & Development (2019 - 2025)
Innate Pharma posted quarterly Research & Development of -$50.8 million for Q4 2025, up 8.59% year-on-year from -$46.8 million in Q4 2024, and down 118.6% on a QoQ basis from -$23.2 million in Q2 2025.
Innate Pharma (IPHA) has 7 years of Research & Development data on file, last reported at -$50.8 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 8.59% year-over-year to -$50.8 million; the trailing twelve-month figure through Dec 2025 stood at -$160.9 million (up 11.31% YoY), and the FY2025 full-year result was $50.8 million, down 8.59% from the prior year.
- Research & Development for Q4 2025 stood at -$50.8 million, down from -$23.2 million in the prior quarter.
- Across five years, Research & Development topped out at $705703.1 in Q2 2021 and bottomed at -$60.3 million in Q4 2023.
- The 5-year median for Research & Development is -$32.8 million (2024), against an average of -$33.5 million.
- The widest annual swing landed in 2021, when Research & Development surged 102.03%; it then plunged 114256.68% in 2023.
- A 5-year view of Research & Development shows it stood at -$53.8 million in 2021, then soared by 99.9% to -$52709.0 in 2022, then sank by 114256.68% to -$60.3 million in 2023, then increased by 7.85% to -$55.5 million in 2024, then increased by 8.59% to -$50.8 million in 2025.
- The last three Research & Development figures came in at -$50.8 million (Q4 2025), -$23.2 million (Q2 2025), and -$55.5 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | -50.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.78 Mn |
| Jun 30, 2025 | -23.23 Mn |
| Dec 31, 2024 | -55.55 Mn |
| Jun 30, 2024 | -31.31 Mn |
| Dec 31, 2023 | -60.28 Mn |
| Jun 30, 2023 | -34.25 Mn |
| Dec 31, 2022 | -52,709.04 |
| Jun 30, 2022 | -26.63 Mn |
| Dec 31, 2021 | -53.77 Mn |
| Jun 30, 2021 | 705,703.06 |
| Dec 31, 2020 | -59.27 Mn |
| Jun 30, 2020 | -34.69 Mn |
| Dec 31, 2019 | -87.27 Mn |
| Jun 30, 2019 | -41.11 Mn |